Related Experiment Videos
cCD79a expression in a case of plasma cell leukemia
M L Alonso1, E Rubiol, R Mateu
1Department of Hematology, Hospital de la Santa Creu i Sant Pau, Secció de Marcadors, Barcelona, Spain.
Leukemia Research
|July 29, 1998
Summary
This study analyzed the immunophenotype of primary plasma cell leukemia (PCL) cells. Researchers found no significant phenotypic differences between bone marrow and peripheral blood, expanding diagnostic markers for PCL.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Primary plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia.
- Understanding the immunophenotype of neoplastic cells is crucial for diagnosis and understanding disease biology.
Observation:
- Simultaneous analysis of bone marrow and peripheral blood samples was performed.
- The immunophenotype of the malignant clone was characterized.
- Minor phenotypic variations between medullary and extramedullary compartments were investigated.
Findings:
- The immunophenotype of the malignant clone was CD38+, CD138+, CD19-, CD56+, CD117-, CD33+, CD44, CD49e, and cCD79a+.
- Cytoplasmic staining for kappa and IgG was positive.
- No major phenotypic differences were observed between bone marrow and peripheral blood neoplastic cells.
Implications:
- The findings support the utility of cytoplasmic CD79a (cCD79a) as a diagnostic marker in PCL, particularly in cases with atypical morphology.
- This research contributes to a better understanding of PCL cell behavior and potential diagnostic strategies.